Cover Image
市場調查報告書

全球免疫學的醫藥品市場預測

Global Immunology Drugs Market to 2022 - Increasing Prevalence, Repositioning Opportunities and Strong Uptake of Interleukin Receptor Inhibitors to Drive Growth

出版商 GBI Research 商品編碼 516017
出版日期 內容資訊 英文 140 Pages
訂單完成後即時交付
價格
Back to Top
全球免疫學的醫藥品市場預測 Global Immunology Drugs Market to 2022 - Increasing Prevalence, Repositioning Opportunities and Strong Uptake of Interleukin Receptor Inhibitors to Drive Growth
出版日期: 2017年05月01日 內容資訊: 英文 140 Pages
簡介

全球免疫學的醫藥品市場,預計從2015年的577億美元,擴大到2022年的754億美元。

本報告提供全球免疫學的醫藥品市場相關調查分析,主要上市產品,開發平台形勢的評估,市場預測,企業分析,策略性整合等系統性資訊。

第1章 目錄

第2章 簡介

第3章 主要上市產品

  • 概要
  • Humira (adalimumab)
  • Enbrel (etanercept)
  • Remicade (infliximab)
  • Rituxan (rituximab)
  • Stelara (ustekinumab)
  • Simponi (golimumab)
  • Prograf (tacrolimus)
  • Cimzia (certolizumab pegol)
  • Entyvio (vedolizumab)
  • Cosentyx (Secukinumab)

第4章 開發平台形勢的評估

  • 概要
  • 開發平台的開發形勢
  • 開發平台的分子標的
  • 臨床試驗
  • 結論

第5章 複數方案的市場預測

  • 市場規模全體
  • 學名藥的普及
  • 收益預測:各分子標的

第6章 企業分析與定位

  • 收益與市場佔有率分析:各企業
  • 企業形勢
  • 上市、產品研發線分析

第7章 策略性整合

  • 授權交易
  • 共同開發交易

第8章 附錄

目錄
Product Code: GBIHC440MR

Executive Summary

Immune-mediated inflammatory diseases are a common set of chronic disorders that affect 5-7% of people in Western populations. Although they are often disparate in terms of their symptoms and key patient demographics, they are pathophysiological linked, being characterized by dysregulation of immune pathways and an inappropriate immune response. Key examples are rheumatoid arthritis (RA), psoriasis, lupus and ankylosing spondylitis.

Immunology is a therapy area characterized by disorders of the immune system, specifically an aberrant autoimmune response against healthy tissues in the body, leading to chronic or acute inflammation. Depending on the specific site affected, this can lead to various types of chronic pain and mobility loss, and have a negative impact on quality of life.

Generally, disease-modifying anti-rheumatic drugs (DMARD) - a highly genericized class of systemic small molecule based agents - are used in the first-line treatment of these diseases. These are supplemented in many cases with shorter-term glucocorticoid therapy, another class of highly genericized systemic agents.

However, as these therapies often fail to elicit an adequate long-term response, a large second-line therapy segment has emerged in these markets, which began with the approval of Remicade (infliximab) and Enbrel (etanercept) in 1998. This segment consists largely of premium systemic monoclonal antibodies (mAb), which are highly commercially successful due to their widespread use and high cost.

Although the patents for many of these mAbs have either already expired or are due to expire during the forecast period, the market is expected to experience continued growth, from $57.7 billion in 2015 to $75.4 billion in 2022, at a compound annual growth rate (CAGR) of 3.88%. This is due to practical and regulatory barriers to entry for biosimilars that are not present for small molecule generics, and a moderately strong late-stage pipeline. There is a large pharmaceutical pipeline for immunology, consisting of 2,054 products in active development. The majority of pipeline products (73%) are in the early stages of development, at either the Preclinical or Discovery stages, but 96 (5%) are in Phase III.

The key market players, namely AbbVie, Johnson & Johnson, Roche, Amgen and Pfizer, are forecast to maintain their strong market shares throughout the forecast period, despite the fact that many of the approaching patent expiries - especially that of adalimumab, marketed by AbbVie, and Remicade, marketed by Johnson & Johnson - will affect these companies directly.

The report "Global Immunology Drugs Market to 2022 - Increasing Prevalence, Repositioning Opportunities and Strong Uptake of Interleukin Receptor Inhibitors to Drive Growth" focuses on four key indications within immunology: Rheumatoid arthritis, Systemic lupus erythematosus (SLE), Psoriasis and Inflammatory bowel disease.

In particular, this report provides the following analysis -

  • Provides an introduction to immunology therapeutics, including disease epidemiology, symptoms, etiology, pathophysiology, co-morbidities and complications and prognosis.
  • Provides an overview of the immunology therapeutics marketed products landscape, including product profiles of key marketed products and revenue projections for each of these drugs.
  • Analyzes the immunology therapeutics pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target, plus an analysis of the key indications in the pipeline. The clinical trial landscape is also examined, with an emphasis on trends in clinical trial failure rates, duration and size.
  • Provides forecast projections to 2022 on a global level, with forecasts provided for the US, plus aggregate revenue forecasts of the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan. Additionally, revenue forecasts for the major product categories and key players are provided.
  • Assesses the company landscape in immunology therapeutics, with an analysis of the key players, the types of company involved in this therapy area and whether this therapy area comprises a large proportion of each company's pipeline portfolio and total revenues.
  • Analyses trends in co-development and licensing deals relating to therapeutic products in immunology.

Companies mentioned in this report: AbbVie, Johnson & Johnson, Roche, Amgen, Pfizer, Celgene, Takeda, Novartis, Eli Lilly, Bristol-Myers Squibb, UCB, Merck & Co, Regeneron, GlaxoSmithKline, Mallinckrodt, Astellas, Sanofi, Shire, Mitsubishi Tanabe, AstraZeneca, Eisai, Ono, Allergan, Biogen, Swedish Orphan Biovitrum, Valeant, Daiichi Sankyo.

Scope

  • Global revenues for the immunology market are forecast to grow at a compound annual growth rate of 3.63%, from $57.7 billion in 2015 to $74.1 billion in 2022.
  • Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
  • The immunological disorders pipeline is large and diverse, and contains 2,054 products. How does the composition of the pipeline compare with that of the existing market?
  • What molecular targets and molecule types are most commonly being trialed in pipeline products in the key indications?
  • Which products will contribute to market growth most significantly, and which will achieve blockbuster status?
  • Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the immunology market set to change?

Reasons to buy

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis
  • Visualize the composition of the immunology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
  • Analyze the immunological disorders pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
  • Understand the growth in patient epidemiology and market revenues for the immunology market, globally and across the key players and product types
  • Stratify the market in terms of the split between generic and premium products, and assess the role of these product types in the treatment of the various immunological disorders.
  • Identify commercial opportunities in the immunology deals landscape by analyzing trends in licensing and co-development deals

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Therapy Area Introduction
    • 2.1.1. Rheumatoid Arthritis
    • 2.1.2. Systemic Lupus Erythematosus
    • 2.1.3. Psoriasis
    • 2.1.4. Inflammatory Bowel Disease
  • 2.2. Symptoms
  • 2.3. Etiology and Pathophysiology
    • 2.3.1. Pathophysiology
  • 2.4. Epidemiology
    • 2.4.1. Rheumatoid Arthritis
    • 2.4.2. Systemic Lupus Erythematosus
    • 2.4.3. Psoriasis
    • 2.4.4. Inflammatory Bowel Disease
  • 2.5. Co-morbidities and Complications
  • 2.6. Treatment
    • 2.6.1. Rheumatoid Arthritis
    • 2.6.2. Systemic Lupus Erythematosus
    • 2.6.3. Psoriasis
    • 2.6.4. Inflammatory Bowel Disease

3. Key Marketed Products

  • 3.1. Overview
  • 3.2. Humira (adalimumab)
  • 3.3. Enbrel (etanercept)
  • 3.4. Remicade (infliximab)
  • 3.5. Rituxan (rituximab)
  • 3.6. Stelara (ustekinumab)
  • 3.7. Simponi (golimumab)
  • 3.8. Prograf (tacrolimus)
  • 3.9. Cimzia (certolizumab pegol)
  • 3.10. Entyvio (vedolizumab)
  • 3.11. Cosentyx (Secukinumab)

4. Pipeline Landscape Assessment

  • 4.1. Overview
  • 4.2. Pipeline Development Landscape
  • 4.3. Molecular Targets in the Pipeline
  • 4.4. Clinical Trials
    • 4.4.1. Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.2. Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.3. Clinical Trial Size
    • 4.4.4. Aggregate Clinical Program Size
    • 4.4.5. Assessment of Key Pipeline Products
  • 4.5. Conclusion

5. Multi-scenario Market Forecast to 2022

  • 5.1. Overall Market Size
  • 5.2. Generic Penetration
  • 5.3. Revenue Forecast by Molecular Target
    • 5.3.1. Tumor Necrosis Factor-Alpha
    • 5.3.2. Interleukin Receptor
    • 5.3.3. B and T Lymphocyte Antigens
    • 5.3.4. Janus Kinases

6. Company Analysis and Positioning

  • 6.1. Revenue and Market Share Analysis by Company
    • 6.1.1. AbbVie - Will the Patent Expiration of Humira Cause a Loss in Market Size?
    • 6.1.2. Pfizer - Xeljanz to Overcome Enbrel Revenue Loss
    • 6.1.3. Johnson & Johnson - Steady Market Leader over Forecast Period
    • 6.1.4. Amgen - Will the Patent Expiration of Enbrel Have an Effect on Overall Immunology Revenue?
    • 6.1.5. Roche - Moderate Revenue Loss Expected due to Biosimilar Competition
    • 6.1.6. Eli Lilly - Approval of RA Drug to Drive Revenue
    • 6.1.7. Bristol-Myers Squibb - Will Biosimilar Competition Affect Orencia Revenue?
    • 6.1.8. Celgene - Otezla and Ozanimod Hydrochloride to Become Blockbuster Drugs
  • 6.2. Company Landscape
  • 6.3. Marketed and Pipeline Portfolio Analysis

7. Strategic Consolidations

  • 7.1. Licensing Deals
    • 7.1.1. Deals by Region, Year and Value
    • 7.1.2. Deals by Stage of Development and Value
    • 7.1.3. Deals by Molecule Type, Mechanism of Action and Value
    • 7.1.4. Licensing Deals Valued over $100m
  • 7.2. Co-development Deals
    • 7.2.1. Deals by Region, Year and Value
    • 7.2.2. Deals by Stage of Development and Value
    • 7.2.3. Deals by Molecule Type, Mechanism of Action and Value
    • 7.2.4. Co-development Deals Valued over $100m

8. Appendix

  • 8.1. References
  • 8.2. Table of All Clinical Stage Pipeline Products
  • 8.3. Abbreviations
  • 8.4. Disease List
  • 8.5. Methodology
    • 8.5.1. Coverage
    • 8.5.2. Secondary Research
    • 8.5.3. Market Size and Revenue Forecasts
    • 8.5.4. Pipeline Analysis
    • 8.5.5. Competitive Landscape
  • 8.6. Contact Us
  • 8.7. Disclaimer

List of Tables

  • Table 1: Immunology Therapeutics Market, Symptoms of RA, SLE, Psoriasis and IBD
  • Table 2: Immunology Therapeutics Market, Etiology of RA, SLE, Psoriasis and IBD
  • Table 3: Immunology, Global, Epidemiology of Inflammatory Immunological Disorders, 2017
  • Table 4: Immunology Therapeutics Market, Global, Approved Indications for Humira, 2017
  • Table 5: Immunology Therapeutics Market, Global, Approved Indications for Enbrel, 2017
  • Table 6: Immunology Therapeutics Market, Global, Approved Indications for Remicade, 2017
  • Table 7: Immunology Therapeutics Market, Global, Approved Indications for Rituxan, 2017
  • Table 8: Immunology Therapeutics Market, Global, Approved Indications for Stelara, 2017
  • Table 9: Immunology Therapeutics Market, Global, Approved Indications for Simponi, 2017
  • Table 10: Immunology Therapeutics Market, Global, Approved Indications for Prograf, 2017
  • Table 11: Immunology Therapeutics Market, Global, Approved Indications for Cimzia, 2017
  • Table 12: Immunology Therapeutics Market, Global, Approved Indications for Entyvio, 2017
  • Table 13: Immunology Therapeutics Market, Global, Approved Indications for Cosentyx, 2017
  • Table 14: Immunology, Global, Annual Revenue Forecast for Key Products ($m), 2015-2022
  • Table 15: Immunology, Global, Usage of Generics Across Key Indications, 2017
  • Table 16: Immunology Therapeutics Market, Global, Forecast Revenues by Company, 2015-2022
  • Table 17: Immunology Therapeutics Market, Global, Licensing Deals Valued over $100m, 2006-2016
  • Table 18: Immunology Therapeutics Market, Global, Co-development Deals Valued over $100m, 2006-2017

List of Figures

  • Figure 1: Immunology, Global, Epidemiology Patterns for Rheumatoid Arthritis ('000), 2016-2023
  • Figure 2: Immunology, Global, Epidemiology Patterns for Systemic Lupus Erythematosus ('000), 2016-2023
  • Figure 3: Immunology, Global, Epidemiology Patterns for Psoriasis ('000), 2016-2023
  • Figure 4: Immunology, Global, Epidemiology Patterns for Inflammatory Bowel Disease ('000), 2016-2023
  • Figure 5: Immunology, Global, Key Marketed Products and Approved Indications, 2016
  • Figure 6: Immunology Therapeutics Market, Global, Annual Revenues for Humira ($bn), 2006-2022
  • Figure 7: Immunology Therapeutics Market, Global, Annual Revenues for Enbrel ($bn), 2006-2022
  • Figure 8: Immunology Therapeutics Market, Global, Annual Revenues for Remicade ($bn), 2006-2022
  • Figure 9: Immunology Therapeutics Market, Global, Annual Revenues for Enbrel ($bn), 2006-2022
  • Figure 10: Immunology Therapeutics Market, Global, Annual Revenues for Stelara ($bn), 2006-2022
  • Figure 11: Immunology Therapeutics Market, Global, Annual Revenues for Simponi ($bn), 2006-2022
  • Figure 12: Immunology Therapeutics Market, Global, Annual Revenues for Prograf ($bn), 2006-2022
  • Figure 13: Immunology Therapeutics Market, Global, Annual Revenues for Cimzia ($bn), 2006-2022
  • Figure 14: Immunology Therapeutics Market, Global, Annual Revenues for Entyvio ($bn), 2006-2022
  • Figure 15: Immunology Therapeutics Market, Global, Annual Revenues for Cosentyx ($bn), 2006-2022
  • Figure 16: Antibacterial Drug Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2017
  • Figure 17: Immunology Therapeutics Market, Global, Pipeline for Immunology by Stage of Development, Molecule Type and Program Type, 2017
  • Figure 18: Immunology Therapeutics Market, Global, Pipeline for Key Immunology Indications by Stage of Development, 2017
  • Figure 19: Immunology Therapeutics Market, Global, Pipeline for Key Immunology Indications by Molecule Type, 2017
  • Figure 20: Immunology Therapeutics Market, Pipeline by Mechanism of Action (%), 2017
  • Figure 21: Immunology Therapeutics Market, Global, Pipeline for Key Immunology Indications by Molecular Target, 2017
  • Figure 22: Immunology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2017
  • Figure 23: Immunology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2017
  • Figure 24: Immunology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2017
  • Figure 25: Immunology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2017
  • Figure 26: Immunology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2017
  • Figure 27: Immunology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2017
  • Figure 28: Immunology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2017
  • Figure 29: Immunology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2017
  • Figure 30: Immunology Therapeutics Market, Global, Clinical Trial Size by Stage of Development (patients), 2006-2017
  • Figure 31: Immunology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2017
  • Figure 32: Immunology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2017
  • Figure 33: Immunology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2017
  • Figure 34: Immunology Therapeutics Market, Global, Clinical Program Size by Stage of Development (months), 2006-2017
  • Figure 35: Immunology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2017
  • Figure 36: Immunology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2017
  • Figure 37: Immunology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2017
  • Figure 38: Immunology Therapeutics Market, Global, Revenue Forecast for sarilumab ($bn), 2016-2022
  • Figure 39: Immunology Therapeutics Market, Global, Revenue Forecast for sirukumab ($m), 2015-2022
  • Figure 40: Immunology, Global, Annual Revenue Forecast for baricitinib ($bn), 2015-2022
  • Figure 41: Immunology, Global, Annual Revenue Forecast for upadacitinib ($m), 2015-2022
  • Figure 42: Immunology, Global, Annual Revenue Forecast for ozanimod ($bn), 2019-2022
  • Figure 43: Immunology, Global, Market Size ($m), 2015-2022
  • Figure 44: Immunology, Global, Annual Revenue Forecast for Key Products ($m), 2015-2022
  • Figure 45: Immunology, Global, Annual Revenue Forecast for Tumor Necrosis Factor-Alpha Inhibitors ($bn), 2015-2022
  • Figure 46: Immunology, Global, Annual Revenue Forecast for Interleukin Inhibitors ($bn), 2015-2022
  • Figure 47: Immunology, Global, Annual Revenue Forecast for B and T Lymphocyte Antigens ($bn), 2015-2022
  • Figure 48: Immunology, Global, Annual Revenue Forecast for Janus Kinases ($bn), 2015-2022
  • Figure 49: Immunology Therapeutics Market, Global, Cluster by Growth and Market Share, 2015-2022
  • Figure 50: Immunology Therapeutics Market, Global, Forecast Market Share by Company (%), 2015-2022
  • Figure 51: Immunology, Global, Companies by Compound Annual Growth Rate (%), 2014-2022
  • Figure 52: Immunology, Global, Revenues by Product Type, 2015-2022
  • Figure 53: Immunology, Global, AbbVie Annual Revenue Forecast ($bn), 2015-2022
  • Figure 54: Immunology, Global, Pfizer Annual Revenue Forecast ($bn), 2015-2022
  • Figure 55: Immunology, Global, Johnson & Johnson Annual Revenue Forecast ($bn), 2015-2022
  • Figure 56: Immunology, Global, Amgen Annual Revenue Forecast ($bn), 2015-2022
  • Figure 57: Immunology, Global, Roche Annual Revenue Forecast ($bn), 2015-2022
  • Figure 58: Immunology, Global, Eli Lilly Annual Revenue Forecast ($bn), 2015-2022
  • Figure 59: Immunology, Global, Bristol-Myers Squib Annual Revenue Forecast ($bn), 2015-2022
  • Figure 60: Immunology, Global, Celgene Annual Revenue Forecast ($bn), 2015-2022
  • Figure 61: Immunology, Global, Companies by Type, 2017
  • Figure 62: Immunology, Global, High-Activity and Late-Stage Pipeline Developers by Level of immunology specialization, 2017
  • Figure 63: Immunology, Global, Proportion of Company Revenue Attributed to immunology, 2015-2022
  • Figure 64: Immunology, Global, Licensing Deals, 2006-2017
  • Figure 65: Immunology, Global, Licensing Deals by Indication and Value, 2006-2017
  • Figure 66: Immunology, Global, Licensing Deals, 2006-2017
  • Figure 67: Immunology, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006-2017
  • Figure 68: Immunology, Global, Co-development Deals, 2006-2017
  • Figure 69: Immunology, Global, Co-development Deals by Indication and Value, 2006-2017
  • Figure 70: Immunology, Global, Co-development Deals, 2006-2017
  • Figure 71: Immunology, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006-2017
  • Figure 72: Immunology, Global, Table of all Clinical Stage Pipeline Products, Part I, 2017
  • Figure 73: Immunology, Global, Table of all Clinical Stage Pipeline Products, Part II, 2017
  • Figure 74: Immunology, Global, Table of all Clinical Stage Pipeline Products, Part III, 2017
  • Figure 75: Immunology, Global, Table of all Clinical Stage Pipeline Products, Part IV, 2017
Back to Top